Is prostate-specific antigen a marker for pregnancies affected by down syndrome?

Clinical Chemistry

Volumn 44, Issue 11, 1998, Pages 2362-2365

  Spencer, Kevin ^a   Carpenter, Paul ^a  

^a HAROLD WOOD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PROSTATE SPECIFIC ANTIGEN;

AMNION FLUID ANALYSIS; ANTIGEN DETECTION; ARTICLE; DIAGNOSTIC ACCURACY; DOWN SYNDROME; ETHNOLOGY; GENETIC SCREENING; HUMAN; MATERNAL DIABETES MELLITUS; PARITY; PRENATAL SCREENING; SCREENING TEST; TRISOMY 21; VARIANCE;

EID: 0031760665     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.11.2362     Document Type: Article

References (26)

1. Cuckle HS, Ellis AR, Seth J. Provision of screening for Down's syndrome. Br Med J 1995;311:512.
2. Palomaki GE, Knight GJ, McCarthy JE, Haddow JE, Donhowe JM. Maternal serum screening for Down syndrome in the United States: a 1995 survey. Am J Obstet Gynecol 1997;176:1046-51.
3. Spencer K, Coombes EJ, Mallard AS, Milford Ward A. Free beta human chorionic gonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers, Ann Clin Biochem 1992;29:506-18.
4. Spencer K. Despistage de la trisomie 21 a l'aide de la beta hCG libre: notre experience sur trois ans. Med Foetale Echographie Gynecol 1994;20:67-9.
5. Macri JN, Spencer K, Garver K, Buchanan PD, Say B, Carpenter NJ, et al. Maternal serum free beta hCG screening: results of studies including 480 cases of Down syndrome. Prenat Diagn 1994;14:97-108.
6. Macri JN, Spencer K. Towards the optimal protocol for Down's syndrome screening. Am J Obstet Gynecol 1996;174:1668-9.
7. Spencer K, Salonen R, Muller F. Down's syndrome screening in multiple pregnancies using alpha fetoprotein and free beta hCG. Prenat Diagn 1994;14:537-42.
8. Reynolds TM, Penney MD, Hughes MD, John R. The effect of weight correction on risk, calculations for Down's syndrome screening. Ann Clin Biochem 1991;28:245-9.
9. Spencer K. Screening for Down's syndrome. The role of intact hCG and free subunit measurements. Scand J Clin Lab Investig 1993;53(Suppl 216):79-96.
10. Neveux LM, Palomaki GE, Larrivee DA, Knight GJ, Haddow JE. Refinements in managing maternal weight adjustment for interpreting prenatal screening results. Prenat Diagn 1196;16:1115-20.
11. Wald NJ, Cuckle HS, Densem JW, Stone RW. Maternal serum unconjugated oestriol and human chorionic gonadotrophin in pregnancies with insulin-dependent diabetes: implications for Down's syndrome screening. Br J Obstet Gynaecol 1992;99:51-3.
12. Palomaki GE, Knight GJ, Haddow JE. Human chorionic gonadotrophin and unconjugated oestriol measurements in insulin-dependent diabetic pregnant women being screened for fetal Down syndrome. Prenat Diagn 1994; 14:65-8.
13. Spencer K. The influence of gravidity on Down's syndrome screening with free beta hCG. Prenat Diagn 1995;15:87-9.
14. Dar H, Merksamer R, Berdichevsky D, David M. Maternal serum marker levels in consecutive pregnancies: a possible genetic predisposition to abnormal levels. Am J Med Genet 1996;61:154-7.
15. Spencer K. Between pregnancy biological variability of maternal serum alpha fetoprotein and free beta hCG: implications for Down syndrome screening in subsequent pregnancies. Prenat Diagn 1997;17:39-45.
16. Spencer K. The influence of smoking on maternal serum AFP and free beta hCG levels and the impact on screening for Down syndrome. Prenat Diagn 1998;18:225-34.
17. Spencer K, Wallace E, Ritoe S. Second trimester dimeric inhibin A in pregnancies affected by Down's syndrome. Prenat Diagn 1996;16:1101-10.
18. Aitken DA, Wallace EM, Crossley J, Swanston IA, Paren Y, Maarle M, et al. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. N Engl J Med 1996;334:1231-6.
19. Cuckle HS, Iles RK, Chard T. Urinary beta core human chorionic gonadotrophin: a new approach to Down's syndrome screening. Prenat Diagn 1994; 14:953-8.
20. Spencer K, Aitken DA, Macri JN, Buchanan PD. Urine free beta hCG and beta core in pregnancies affected by Down's syndrome. Prenat Diagn 1996;16: 605-13.
21. Spencer K, Souter V, Nicolaides KH. A rapid first trimester screening program for Down syndrome using nuchal translucency, free beta hCG and PAPP-A. Ultrasound Obstet Gynaecol (in press).
22. Lambert-Messerlian GM, Canick JA, Melegos DN, Diamandis EP. Increased concentrations of prostate-specific antigen in maternal serum from pregnancies affected by fetal Down syndrome. Clin Chem 1998;44:205-8.
23. Melegos DN, Yu H, Allen L, Diamandis EP. Prostate specific antigen in amniotic fluid of normal and abnormal pregnancies. Clin Biochem 1996;29: 552-62.
24. Ferguson RA, Yu H, Zammit S, Diamandis EP. Ultrasensitive detection of prostate-specific antigen by a time resolved immunofluorometric assay and the Immulite immunochemiluminescent third generation assay: potential applications in prostate and breast cancers. Clin Chem 1996;42:675-84.
25. Spencer K, Muller F, Aitken DA. Biochemical markers of trisomy 21 in amniotic fluid. Prenat Diagn 1997;17:31-7.
26. Spencer K, Muller F, Aitken DA. Amniotic fluid and maternal serum levels of CA125 in pregnancies affected by Down syndrome: a re-evaluation of the role of CA125 in Down syndrome screening. Prenat Diagn 1997;17:701-6.